Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm to Participate in the 31st Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in the 31st Annual Piper
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2019 Financial Results
Third quarter revenue decreased 8.5 percent to $26.5 million ; year-to-date revenue increased 5 percent to $84.8 million Third quarter consumables revenue increased 11 percent Year-to-date mass cytometry revenue increased 28 percent More than 10 new products commercialized in the quarter SOUTH SAN
View HTML
Toggle Summary Fluidigm Drives a New Standard in Human Immune Profiling
More than 100 Academic, Pharmaceutical and Biotech Companies Select Maxpar Immune Profiling Panels Using CyTOF Technology to Accelerate Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM) today announced it has
View HTML
Toggle Summary Fluidigm Showcases RNA Sequencing Innovations Using Microfluidics Technology at the 2019 American Society of Human Genetics (ASHG) Meeting
Delivering automated RNA workflows to significantly reduce cost per sample and hands-on time using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report third quarter 2019 financial results on Tuesday,
View HTML
Toggle Summary Fluidigm Becomes the First Company to Enable 50-Plex Cytometry Panels with the Release of Seven New Metal Antibody Labels
Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research   SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO)
Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific
View HTML
Toggle Summary Fluidigm Files Patent Infringement Suit Against IONpath
SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court
View HTML
Toggle Summary Fluidigm Revolutionizes Next-Generation Sequencing RNA Library Preparation with Microfluidic Automation
Fluidigm Launches Breakthrough RNA Sequencing Library Preparation Workflow, Delivering Substantial Cost Savings and Efficiency SOUTH SAN FRANCISCO, Calif. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve
View HTML
Toggle Summary Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)
Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today
View HTML